To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Discovery and validation … - University of Gothenburg, Sweden Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay.

Journal article
Authors Liu Shi
Sarah Westwood
Alison L Baird
Laura Winchester
Valerija Dobricic
Fabian Kilpert
Shengjun Hong
Andre Franke
Abdul Hye
Nicholas Ashton
Angharad R Morgan
Isabelle Bos
Stephanie J B Vos
Noel J Buckley
Mara Ten Kate
Philip Scheltens
Rik Vandenberghe
Silvy Gabel
Karen Meersmans
Sebastiaan Engelborghs
Ellen E De Roeck
Kristel Sleegers
Giovanni B Frisoni
Olivier Blin
Jill C Richardson
Régis Bordet
José L Molinuevo
Lorena Rami
Anders Wallin
Petronella Kettunen
Magda Tsolaki
Frans Verhey
Alberto Lleó
Daniel Alcolea
Julius Popp
Gwendoline Peyratout
Pablo Martinez-Lage
Mikel Tainta
Peter Johannsen
Charlotte E Teunissen
Yvonne Freund-Levi
Lutz Frölich
Cristina Legido-Quigley
Frederik Barkhof
Kaj Blennow
Henrik Zetterberg
Susan Baker
B Paul Morgan
Johannes Streffer
Pieter Jelle Visser
Lars Bertram
Simon Lovestone
Alejo J Nevado-Holgado
Published in Alzheimer's & dementia : the journal of the Alzheimer's Association
ISSN 1552-5279
Publication year 2019
Published at Institute of Neuroscience and Physiology
Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry
Wallenberg Centre for Molecular and Translational Medicine
Language en
Links dx.doi.org/10.1016/j.jalz.2019.06.4...
www.ncbi.nlm.nih.gov/entrez/query.f...
Subject categories Psychiatry, Neurosciences

Abstract

Plasma proteins have been widely studied as candidate biomarkers to predict brain amyloid deposition to increase recruitment efficiency in secondary prevention clinical trials for Alzheimer's disease. Most such biomarker studies are targeted to specific proteins or are biased toward high abundant proteins.4001 plasma proteins were measured in two groups of participants (discovery group = 516, replication group = 365) selected from the European Medical Information Framework for Alzheimer's disease Multimodal Biomarker Discovery study, all of whom had measures of amyloid.A panel of proteins (n = 44), along with age and apolipoprotein E (APOE) ε4, predicted brain amyloid deposition with good performance in both the discovery group (area under the curve = 0.78) and the replication group (area under the curve = 0.68). Furthermore, a causal relationship between amyloid and tau was confirmed by Mendelian randomization.The results suggest that high-dimensional plasma protein testing could be a useful and reproducible approach for measuring brain amyloid deposition.

Page Manager: Webmaster|Last update: 9/11/2012
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?